Acute Myeloid Leukemia Market

Report Overview

According to the deep-dive market assessment study by Growth+ Reports, the global acute myeloid leukemia market was valued at US$ 1.8 billion in 2021. The market is expected to witness a CAGR of 10.2% from 2022 to 2030.

Market Fundamentals

Acute myeloid leukemia (AML) is a type of hematologic cancer distinguished by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and other tissues. AML is caused by a series of genetic changes in a hematopoietic precursor cell. Leukemic cells proliferate in the bone marrow and interfere with normal blood cell production, resulting in weakness, infection, bleeding, and other symptoms and complications. While recurrent acquired genetic abnormalities have been discovered in leukemia blasts, most patients' direct causes of AML are unknown.

[4634534]

Market Dynamics 

The rising incidence rate of acute myeloid leukemia and the increased death rate among patients globally are the major driving factors of the global acute myeloid leukemia market. Moreover, the growing geriatric population is increasing the patient pool for acute myeloid leukemia. The increased advancement in pharmacology and molecular biology to promote drug development is also propelling the growth in the global market. Additionally, the government and non-government organizations taking initiatives to create awareness regarding early diagnosis and treatment of different cancer are also increasing the demand for acute myeloid leukemia treatment. Similarly, the rise in the research related to targeted therapies and biologics is also playing a pivotal role in the growth of the global acute myeloid leukemia market. The rise in unhealthy lifestyles, such as tobacco smoking and alcohol consumption, is also increasing the patient pool for acute myeloid leukemia.

Furthermore, with increased investment in research and development, more clinical trials are being conducted to demonstrate the efficacy of the drugs, which is also expected to boost the global acute myeloid leukemia market. However, the high cost of acute myeloid leukemia treatment products such as biologics, chemotherapy, and targeted therapies is the major restricting factor of the global acute myeloid leukemia market. Moreover, the lack of skilled professionals and awareness in developing countries is also hindering market growth. 

Market Ecosystem

The global acute myeloid leukemia market has been analyzed from two perspectives: drug class, and region. 

Acute Myeloid Leukemia Market by Drug Class 

[78667554]

Based on drug class, the global acute myeloid leukemia market is segmented into antineoplastics, kinase inhibitors, hedgehog pathway inhibitors, and others (including combinations). The antineoplastics segment dominates the global acute myeloid leukemia market with the largest market share in 2021. The large share of the antineoplastics segment can largely be attributed to the excellent demand for antineoplastics drugs as it is the most commonly used drug for cancer. Moreover, the overall survival rate of people who are treated with antineoplastics is thus increasing the demand for antineoplastics drugs. Additionally, these drugs are used as primary treatment for most cancers. According to the National Cancer Institute’s SEER*RX database, more than 2000 antineoplastic drugs exist. Similarly, rising Cytarabine approvals by the US Food and Drug Administration for treating acute myeloid leukemia are also expected to drive the segment growth.

Acute Myeloid Leukemia Market by Region 

Based on region, the global acute myeloid leukemia market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the global acute myeloid leukemia market in 2021, followed by Europe. Asia Pacific market is anticipated to grow at the fastest CAGR during the forecast period. The large share of North America can largely be attributed to the rising prevalence of acute myeloid leukemia. According to the American Society of Clinical Oncology, in 2021, an estimated 20,240 people of all ages (11,230 men and boys and 9,010 women and girls) will be diagnosed with this disease in the United States. Acute myeloid leukemia is the second most common type of leukemia in both adults and children, with adults accounting for the vast majority of cases. Furthermore, increasing research & development and product launches for acute myeloid leukemia are boosting the market growth in this region. The presence of well-developed healthcare infrastructure and the top market players in the region is also expected to propel regional growth.

Competitive Landscape

The prominent players operating in the global acute myeloid leukemia market are:

• Pfizer Inc.
• Genentech Inc.
• Novartis AG
• Astellas Pharma Inc.
• Bristol-Myers Squibb Company
• Servier Laboratories
• Jazz Pharmaceuticals plc
• Celgene Corporation
• AROG Pharmaceuticals
• Astex Pharmaceuticals
• Actinium Pharmaceuticals
• GlycoMimetics
• Rafael Pharmaceuticals
• F. Hoffmann-La Roche Ltd.
• Takeda Oncology
• Helsinn Healthcare
• Tolero Pharmaceuticals
• Syros Pharmaceuticals

Strategic Developments

• In July 2022, Escend Pharmaceuticals received FDA approval for the Investigational New Drug (IND) application for the phase I study of its potential lead drug ES-3000. The ES-3000 is an orally bioavailable small molecule that prohibits the leukemic stem cells by reducing β-catenin expression.
• In June 2022, Daiichi Sankyo announced positive results from the global pivotal QuANTUM-First phase 3 trial for quizartinib combined with standard induction and consolidation chemotherapy. The statistics show improvement in the overall survival rate of the patients aged 18-75 with newly diagnosed FLT3-ITD positive acute myeloid leukemia. 
• In May 2022, Servier received approval from the FDA for TIBSOVO in combination with azacytidine for the treatment of newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in adults 75 years or older.

Frequently Asked Questions About This Report